Rani Therapeutics Holdings Inc Dossier - Source-backed chat

Rani Therapeutics Holdings Inc

RANINASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.77

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.80Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $111.8M

Enterprise Value $106.9M

Shares Outstanding 145.1M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rani Therapeutics is a clinical-stage biotherapeutics company pioneering the oral delivery of large-molecule biologics through its proprietary RaniPill platform. By replacing painful subcutaneous injections and intravenous infusions with a convenient oral capsule, Rani addresses a massive market opportunity across obesity, osteoporosis, and immunology. The company's recent strategic collaboration with Chugai Pharmaceutical (valued up to $1.085 billion) and its partnership with ProGen for the GLP-1/GLP-2 dual agonist RT-114 validate the platform's commercial potential. Despite near-term delisting risks and cash burn typical of clinical-stage biotech, Rani's successful $20 million direct offering in May 2026 and its extended cash runway into late 2027 provide a solid foundation to reach critical clinical inflection points, including the RT-102 Phase 2 readout in late 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$7.50

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The bear case reflects potential clinical delays, safety concerns with the RaniPill mechanical delivery mechanism in human trials, or failure to achieve bioequivalence. Additionally, inability to regain Nasdaq compliance could lead to delisting, severely limiting capital access and accelerating dilution through highly discounted equity raises.

Base CaseCentral scenario

$7.5055%

Matches the consensus mean

The base case assumes steady clinical execution of the ongoing RT-114 Phase 1 trial and the initiation of the RT-101 Phase 2 study by mid-2026. The company successfully regains Nasdaq compliance (potentially via a reverse stock split or market transfer) and maintains its cash runway into late 2027 through disciplined expense management and technology transfer milestones from Chugai.

Bull CaseUpside scenario

$13.0025%

The bull case is driven by outstanding clinical success of the RaniPill platform, particularly bioequivalence validation for RT-114 (obesity) and positive Phase 2 results for RT-102 (osteoporosis) in late 2026. This triggers substantial milestone payments from Chugai and ProGen, attracts additional global pharmaceutical partnerships, and secures non-dilutive funding, driving rapid valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary RaniPill platform capable of delivering any biologic payload orally with high bioavailability.
High-value strategic partnerships, including a $1.085 billion collaboration with Chugai and a worldwide collaboration with ProGen.
Strengthened balance sheet following a $20 million registered direct offering in May 2026, extending the cash runway into Q4 2027.
Strong pipeline targeting multi-billion dollar markets in obesity (RT-114, RT-116), osteoporosis (RT-102), and immunology (RT-111).

Key Investment Risks

Clinical development risk, including potential safety, tolerability, or bioequivalence failures of the RaniPill platform.
Nasdaq delisting risk due to the company's share price trading below the $1.00 minimum bid price requirement.
High cash burn and ongoing need for dilutive capital raises before achieving commercialization.
Reliance on third-party partners for drug supply and co-development milestones.

Thesis Invalidation Triggers

Failure of RT-114 to demonstrate bioequivalence or acceptable safety in its Phase 1 trial.
Negative or inconclusive topline Phase 2 results for RT-102 in osteoporosis.
Termination of the Chugai or ProGen collaboration agreements.
Delisting from the Nasdaq Global Market due to failure to regain compliance with the minimum bid price rule.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.